Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
UTD2 is the world's first oral epothilone microtubule inhibitor
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Subscribe To Our Newsletter & Stay Updated
